James E. Levine - 15 Mar 2023 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Reporting relationship: Chief Financial Officer
Issuer ticker: CRDF
Reported as of: 15 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2023, 17:42:11 UTC
Prior SEC filing: 19 Sep 2022
Next SEC filing: 07 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ James Levine

Key filing fact

James E. Levine filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 16 Mar 2023.

Key facts

This page summarizes James E. Levine's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2023, 17:42.

Change

Previous filing in this sequence was filed on 19 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRDF transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +197,472
Change %: +35%
Price: $0.000000
Shares after: 757,488
Date: 15 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 197,472
Exercise price: $1.72
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option will vest on March 15, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.